SCHEMBL6400748

SCHEMBL6400748

CC(C)(CC(=O)O)C(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.53
HIF1A Q16665 1/20 0.53
CES1 P23141 7/20 0.48
SRC P12931 1/20 0.44
PRSS1 P07477 1/20 0.42
CTSG P08311 1/20 0.42
CTRB1 P17538 1/20 0.42
CMA1 P23946 1/20 0.42
NR4A2 P43354 1/20 0.42
POLB P06746 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28466783 0.86 CES1 (0.47) CYP2C19HIF1ACES1SRCPRSS1
Hydrogen Peroxide SCHEMBL29060971 0.83 CES1 (0.52) CYP2C19HIF1ACES1SRCPRSS1
SCHEMBL1728463 0.83 CES1 (0.52) CYP2C19HIF1ACES1SRCPRSS1
SCHEMBL4881466 0.82 HIF1A (0.52) CYP2C19HIF1ACES1SRCNR4A2
SCHEMBL14632295 0.81 PPARG (0.45) CYP2C19HIF1APRSS1KDM4EHPGD
SCHEMBL5183124 0.81 SRC (0.51) CYP2C19HIF1ACES1SRCPRSS1
SCHEMBL6223670 0.81 RIPK1 (0.50) CYP2C19CES1SRCPRSS1CTSG
SCHEMBL3933601 0.81 CES1 (0.50) CYP2C19HIF1ACES1SRCPRSS1
SCHEMBL759622 0.81 CES1 (0.50) CYP2C19HIF1ACES1SRCPRSS1
SCHEMBL29922425 0.81 TP53BP1 (0.49) CYP2C19KDM4EMEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497272-B2 Compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-07-30 US disclosed
US-20110245262-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2011-10-06 US disclosed
US-20070004735-A1 Method for inhibiting the replication of herpes viruses AICURIS GMBH & CO. KG (DE) 2007-01-04 US disclosed
US-20070004735-A1 Method for inhibiting the replication of herpes viruses AICURIS GMBH & CO. KG (DE) 2007-01-04 US disclosed
US-20050059658-A1 Pyridazinone BAYER AKTIENGESELLSCHAFT (DE) 2005-03-17 US disclosed
EP-1404657-A1 PYRIDAZINONE Bayer HealthCare AG (DE) 2004-04-07 EP disclosed
WO-2003002541-A1 PYRIDAZINONE BAYER HEALTHCARE AG (DE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059658-A1 Pyridazinone TYMP, TPMT, PDXK CYP2C19 741/4885HIF1A 4167/4885CES1 3292/4885
US-20110245262-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS HSP90AB1, HSF1, HSP90B1 CYP2C19 4453/4885HIF1A 2925/4885CES1 4089/4885
US-20070004735-A1 Method for inhibiting the replication of herpes viruses RPL35, PCNA, MCM5 CYP2C19 4543/4885HIF1A 817/4885CES1 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.